Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 12/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5021078 | 0.94 | GBA1 (0.56) | GBA1HRH4HRH3 | |
| SCHEMBL21555593 | 0.92 | GBA1 (0.58) | GBA1HRH4HRH3 | |
| SCHEMBL3550825 | 0.92 | GBA1 (0.58) | GBA1HRH4HRH3 | |
| SCHEMBL19604902 | 0.92 | GBA1 (0.58) | GBA1HRH4HRH3 | |
| SCHEMBL12299387 | 0.90 | GBA1 (0.51) | GBA1HRH4HRH3 | |
| SCHEMBL12299383 | 0.90 | GBA1 (0.51) | GBA1HRH4HRH3 | |
| SCHEMBL1753962 | 0.88 | GBA1 (0.45) | GBA1HRH4HRH3CYP19A1 | |
| SCHEMBL5020804 | 0.86 | HRH4 (0.58) | GBA1HRH4HRH3CYP19A1 | |
| SCHEMBL3536027 | 0.86 | CYP19A1 (0.56) | GBA1HRH4HRH3CYP19A1 | |
| SCHEMBL15958720 | 0.85 | HRH4 (0.65) | GBA1HRH4HRH3CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023239750-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-10-19 | — | — | US | disclosed |
| WO-2022261250-A1 | THERAPEUTICS FOR THE DEGRADATION OF MUTANT BRAF | C4 THERAPEUTICS, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2021102052-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. (US) | 2021-05-27 | — | — | WO | disclosed |
| US-11014970-B2 | Modifications and uses of conotoxin peptides | KINETA CHRONIC PAIN, LLC (US) | 2021-05-25 | — | — | US | disclosed |
| WO-2020236969-A1 | COMPOSITIONS AND METHODS RELATING TO DETECTION, INHIBITION, AND IMAGING OF INDOLEAMINE 2,3-DIOXYGENASE 1 (IDO1) | INDI MOLECULAR, INC. (US) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020142102-A9 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | KINETA CHRONIC PAIN, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200237924-A1 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | KINETA CHRONIC PAIN, LLC (US) | 2020-07-30 | — | — | US | disclosed |
| WO-2020142102-A1 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | KINETA CHRONIC PAIN, LLC (US) | 2020-07-09 | — | — | WO | disclosed |
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapetics Inc. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20110311516-A1 | Chemically Programmed Vaccination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC., A DELAWARE CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7981999-B2 | Peptidomimetics; kits; macrocyclization | AILERON THERAPEUTICS, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | AILERON THERAPEUTICS, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | AILERON THERAPEUTICS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2010-08-26 | — | — | US | disclosed |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2008104000-A2 | TRIAZOLE MACROCYCLE SYSTEMS | AILERON THERAPEUTICS, INC. (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101047-A1 | PEPTIDOMIMETIC MACROCYCLES | GLP1R, PROKR1, VIP | GBA1 669/4885HRH4 1851/4885HRH3 2016/4885 |
| US-20110263815-A1 | TRIAZOLE MACROCYCLE SYSTEMS | FLT3, VIP, NGLY1 | GBA1 4570/4885HRH4 1806/4885HRH3 1158/4885 |
| US-20110223149-A1 | PEPTIDOMIMETIC MACROCYCLES | PREP, ANPEP, DNPEP | GBA1 1017/4885HRH4 4083/4885HRH3 3193/4885 |
| US-20100216688-A1 | PEPTIDOMIMETIC MACROCYCLES | CCL2, TAP2, TAP1 | GBA1 2752/4885HRH4 4334/4885HRH3 3879/4885 |
| US-20200237924-A1 | CONOTOXIN PEPTIDE ANALOGS AND USES FOR THE TREATMENT OF PAIN AND INFLAMMATORY CONDITIONS | CHRNG, CHRNA9, CHRNA10 | GBA1 2233/4885HRH4 1173/4885HRH3 1240/4885 |
| US-20110144303-A1 | Biologically Active Peptidomimetic Macrocycles | VIP, ANPEP, DNPEP | GBA1 280/4885HRH4 4460/4885HRH3 3972/4885 |
| US-20100298201-A1 | PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES | VIP, ANPEP, NGLY1 | GBA1 946/4885HRH4 4246/4885HRH3 3700/4885 |
| US-20110311516-A1 | Chemically Programmed Vaccination | CD69, CD4, ICOS | GBA1 3962/4885HRH4 1888/4885HRH3 648/4885 |
| US-20090275519-A1 | Therapeutic peptidomimetic macrocycles | PCNA, MKI67, NFATC1 | GBA1 2876/4885HRH4 3022/4885HRH3 2281/4885 |
| US-11014970-B2 | Modifications and uses of conotoxin peptides | CHRNA9, CHRNA10, CHRNA7 | GBA1 1436/4885HRH4 637/4885HRH3 801/4885 |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | HAVCR2, ACE2, EPCAM | GBA1 1518/4885HRH4 4345/4885HRH3 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.